The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (EXPLORE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04437368
Recruitment Status : Active, not recruiting
First Posted : June 18, 2020
Last Update Posted : February 26, 2024
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Gyroscope Therapeutics Limited

Brief Summary:
The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD).

Condition or disease Intervention/treatment Phase
Dry Age-related Macular Degeneration Drug: GT005; Low Dose Drug: GT005; High Dose Phase 2

Detailed Description:

This is a Phase 2, outcomes assessor-masked, multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD.

The trial includes a screening period of up to 8 weeks followed by a 96-week study period.

Subjects will be randomised to one of two arms: GT005 or the untreated control group.

Part 1 is conducted in a genetically selective sub-group of patients with GA secondary to AMD.

Part 2 is conducted in a non-genetically selective sub-group of patients with GA secondary to AMD.

This study is terminating early due to the interim analysis demonstrating lack of treatment efficacy. No additional subjects will be randomized or dosed. The trial is not ending early because of medical problems.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 98 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a Phase 2, outcomes assessor-masked multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD.
Masking: Single (Outcomes Assessor)
Masking Description: Participant, Care provider, Investigators and Sponsor are dose masked in Part 1. Part 2 is open label study. Primary outcome assessor is fully masked to the treatment status in both Part 1 and Part 2.
Primary Purpose: Treatment
Official Title: EXPLORE: A Phase II, Outcomes Assessor-masked, Multicentre, Randomised Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
Actual Study Start Date : July 14, 2020
Estimated Primary Completion Date : March 29, 2024
Estimated Study Completion Date : March 29, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part 1 - GT005 Low Dose
Approximately 25 subjects are planned, with subjects randomised to GT005 Low Dose.
Drug: GT005; Low Dose
Part 1 of the study will test two doses of GT005: Low Dose and High Dose.

Experimental: Part 1 - GT005 High Dose
Approximately 25 subjects are planned, with subjects randomised to GT005 High Dose.
Drug: GT005; High Dose
Part 1 of the study will test two doses of GT005: Low Dose and High Dose.

No Intervention: Part 1 - Untreated control
Approximately 25 subjects are planned, with subjects randomised to untreated control.
Experimental: Part 2 - GT005 Low Dose
Approximately 116 subjects are planned, with subjects randomised to Part 2 - GT005 Low Dose.
Drug: GT005; Low Dose
Part 2 of the study will test one dose: Low Dose.

No Intervention: Part 2 - Untreated control
Approximately 54 subjects are planned, with subjects randomised to untreated control.



Primary Outcome Measures :
  1. Progression of geographic atrophy [ Time Frame: 48 weeks ]
    The change from baseline to Week 48 in GA area as measured by fundus autofluorescence (FAF)


Secondary Outcome Measures :
  1. Progression of geographic atrophy [ Time Frame: 96 weeks ]
    The change from baseline through Week 96 in GA area as measured by fundus autofluorescence (FAF)

  2. Evaluation of the safety and tolerability of GT005 [ Time Frame: 96 weeks ]
    Frequency of treatment emergent adverse events (AEs) through Week 96

  3. Evaluation of the effect of GT005 on retinal anatomical measures [ Time Frame: 96 weeks ]
    Change in retinal morphology on multimodal imaging through Week 96

  4. Evaluation of the effect of GT005 on functional measures [ Time Frame: 96 weeks ]
    Change in BCVA Score via the early treatment for diabetic retinopathy (ETDRS) chart through Week 96

  5. Evaluation of the effect of GT005 on functional measures [ Time Frame: 96 weeks ]
    Change in low luminance difference (LLD) via the ETDRS chart through Week 96

  6. Evaluation of the effect of GT005 on visual function [ Time Frame: 96 weeks ]
    Change in reading performance as assessed by Minnesota low-vision reading test (MNRead) Chart through Week 96

  7. Evaluation of the effect of GT005 on visual function [ Time Frame: 96 weeks ]
    Change in functional reading independence (FRI) index through Week 96

  8. Evaluation of the effect of GT005 on patient-reported outcomes [ Time Frame: 96 weeks ]
    Change in quality of life measured on the Visual Functioning Questionnaire-25 (VFQ-25) through Week 96



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able and willing to give written informed consent
  2. Age ≥55 years
  3. Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, and a diagnosis of AMD in the contralateral eye (except if the subject is monocular)
  4. Have GA lesion(s) total size between or equal to 1.25mm2 to 17.5mm2 in the study eye
  5. The GA lesion(s) in the study eye must reside completely within the FAF image
  6. Up to 25% of the enrolled study population are permitted to have CNV in the fellow eye, defined as either:

    1. Non-exudative/sub-clinical fellow eye CNV identified at Screening, or
    2. Known history of fellow eye CNV with either ≥2 years since diagnosis or with no active treatment required in 6 months prior to Screening
  7. Have a BCVA of 24 letters (6/95 and 20/320 Snellen acuity equivalent) or better, using ETDRS charts, in the study eye
  8. Part 1 Only: Subjects carrying a CFI rare variant genotype (minor allele frequency of ≤1%) previously associated with low serum CFI or subjects carrying an unreported CFI rare variant genotype that have tested to have a low serum CFI
  9. Able to attend all study visits and complete the study procedures
  10. Women of child-bearing potential must have a negative pregnancy test within 2 weeks prior to randomisation. A pregnancy test is not required for postmenopausal women (defined as being at least 12 consecutive months without menses) or those surgically sterilised (those having a bilateral tubal ligation/bilateral salpingectomy, bilateral tubal occlusive procedure, hysterectomy, or bilateral oophorectomy)

Exclusion Criteria:

  1. Subjects who have a clinical diagnosis of Stargardt Disease or other retinal dystrophies, confirmed by the central reading centre
  2. Have a history, or evidence, of CNV in the study eye
  3. Presence of moderate/severe or worse non-proliferative diabetic retinopathy in the study eye
  4. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the study eye
  5. History of intraocular surgery in the study eye within 12 weeks prior to Screening (Visit 1). Yttrium aluminium garnet capsulotomy is permitted if performed >10 weeks prior to Visit 1
  6. Have clinically significant cataract that may require surgery during the study period in the study eye
  7. Presence of moderate to severe glaucomatous optic neuropathy in the study eye; uncontrolled IOP despite the use of two or more topical agents; a history of glaucoma-filtering or valve surgery is also excluded
  8. Axial myopia of greater than -8 dioptres in the study eye
  9. Have any other significant ocular or non-ocular medical or psychiatric condition which, in the opinion of the Investigator, may either put the subject at risk or may influence the results of the study
  10. Have a contraindication to specified protocol corticosteroid regimen
  11. Have received any investigational and/or approved product(s) for the treatment of GA within the past 6 months, or 5 half-lives (whichever is longer) other than nutritional supplements such as the age-related eye disease study (AREDS) formula in the study eye or systemically
  12. Have received a gene or cell therapy at any time
  13. Are unwilling to use two forms of contraception (one of which being a barrier method) for 90 days post-dosing, if relevant
  14. Active malignancy within the past 12 months, except for: appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with a stable prostate-specific antigen (PSA) ≥12 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04437368


Locations
Show Show 55 study locations
Sponsors and Collaborators
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Gyroscope Therapeutics Limited
ClinicalTrials.gov Identifier: NCT04437368    
Other Study ID Numbers: GT005-02
CPPY988A12202 ( Other Identifier: Novartis )
First Posted: June 18, 2020    Key Record Dates
Last Update Posted: February 26, 2024
Last Verified: February 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gyroscope Therapeutics Limited:
Geographic atrophy
Retinal disease
Eye disease
Retinal degeneration
Macular atrophy
Dry age-related macular degeneration
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Geographic Atrophy
Retinal Degeneration
Retinal Diseases
Eye Diseases